Literature DB >> 2205369

Comprehensive management of locally advanced breast cancer.

G N Hortobagyi1.   

Abstract

The definition of locally advanced breast cancer includes patients with large tumors, extensive regional lymph node involvement, or direct involvement of the skin or underlying chest wall. Most of these patients have very poor survival with standard treatment modalities, and over the past 20 years combined modality therapy has been used to improve local and systemic control. There is limited information suggesting that patients with operable locally advanced breast cancer have an improved survival if treated with surgery (or radiation therapy) followed by systemic chemotherapy, as compared with patients treated with local modalities alone. Uncontrolled trials strongly suggest that patients with any stage of locally advanced breast cancer achieve high response rates after induction chemotherapy. Most of these patients can be rendered disease free after combined modality therapy, and their disease-free and overall survival rates appear to be improved when compared with historical controls. These results are most impressive for patients with inflammatory breast cancer, a disease previously found to be uniformly lethal when treated with local modalities of therapy alone. More recently, 30% to 50% of these patients were alive and disease free 5 years after diagnosis, and a substantial percentage were in the same condition 10 years later. Combined modality therapies are the most appropriate approach to patients with locally advanced breast cancer. Much additional research must be done to improve the results of these therapies and maximize the survival of patients with locally advanced breast cancer.

Entities:  

Mesh:

Year:  1990        PMID: 2205369     DOI: 10.1002/1097-0142(19900915)66:14+<1387::aid-cncr2820661414>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  An RF phased array applicator designed for hyperthermia breast cancer treatments.

Authors:  Liyong Wu; Robert J McGough; Omar Ali Arabe; Thaddeus V Samulski
Journal:  Phys Med Biol       Date:  2005-12-15       Impact factor: 3.609

2.  Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response.

Authors:  Malathy P V Shekhar; Laura A Biernat; Nat Pernick; Larry Tait; Judith Abrams; Daniel W Visscher
Journal:  Med Oncol       Date:  2009-05-23       Impact factor: 3.064

3.  (99m)Tc-sestamibi scintigraphy used to evaluate tumor response to neoadjuvant chemotherapy in locally advanced breast cancer: A quantitative analysis.

Authors:  Katia Hiromoto Koga; Sonia Marta Moriguchi; Jorge Nahás Neto; Stela Verzinhasse Peres; Eduardo Tinóis DA Silva; Almir José Sarri; Odair Carlito Michelin; Mariangela Esther Alencar Marques; Beatriz Lotufo Griva
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

4.  Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.

Authors:  Konstantinos Papadimitriou; Konstantinos Papademetriou; Alexandros Ardavanis; Panteleimon Kountourakis
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

Review 5.  Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?

Authors:  V Mandilaras; N Bouganim; J Spayne; R Dent; A Arnaout; J F Boileau; M Brackstone; S Meterissian; M Clemons
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

6.  Evaluation of neoadjuvant chemotherapy response in women with locally advanced breast cancer using ultrasound elastography.

Authors:  Omar Falou; Ali Sadeghi-Naini; Sameera Prematilake; Ervis Sofroni; Naum Papanicolau; Sara Iradji; Zahra Jahedmotlagh; Sharon Lemon-Wong; Jean-Philippe Pignol; Eileen Rakovitch; Judit Zubovits; Jacqueline Spayne; Rebecca Dent; Maureen Trudeau; Jean Francois Boileau; Frances C Wright; Martin J Yaffe; Gregory J Czarnota
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

7.  Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy.

Authors:  Omar Falou; Hany Soliman; Ali Sadeghi-Naini; Sara Iradji; Sharon Lemon-Wong; Judit Zubovits; Jacqueline Spayne; Rebecca Dent; Maureen Trudeau; Jean Francois Boileau; Frances C Wright; Martin J Yaffe; Gregory J Czarnota
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

Review 8.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer.

Authors:  Zhi-Heng Huang; Xing-Song Tian; Rong Li; Xian-Ming Wang; Wen Wen; Hong Guan; Ya-Jie Yang
Journal:  Exp Ther Med       Date:  2011-11-28       Impact factor: 2.447

10.  Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy.

Authors:  Albert Cerussi; David Hsiang; Natasha Shah; Rita Mehta; Amanda Durkin; John Butler; Bruce J Tromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.